Study raises concerns that new antibiotics will do little to solve the resistance problem if the drugs are used inappropriately once they are introduced
UK medicines regulator seeks to allay pharma industry concern, reiterating a previous promise it will be pragmatic in setting new UK drugs rules in event of no-deal Brexit
Sector deal features 25 investments from global companies and a pledge by government to provide funding for research infrastructure and long-term capital to allow start-ups to scale
Only 5 of 19 cities bidding to host the European Medicines Agency would attract enough current employees for operations to continue as normal. Moving to one of the 8 least popular cities risks permanent damage, the agency warns
As WHO warns the antibiotics pipeline does not address the threat of bacterial resistance, the EU must step up and do more to galvanise R&D, accelerate innovation and help shape a coordinated global response to the impending crisis
The University of Amsterdam (UvA)’s Faculty of Science, UvA Ventures Holding B.V. and Innovation Exchange Amsterdam (IXA-UvA) are pooling their resources to fund Macrobian Biotech BV, a single asset biotech company that will further develop medicine for the treatment of Parkinson’s disease.
Receive the Funding Newswire [full access requires a subscription] each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening.
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.